Editas Medicine, Inc. (FRA:8EM)
Germany · Delayed Price · Currency is EUR 1.870
-0.188 (-9.12%)
At close: Dec 1, 2025
Editas Medicine Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 46.38 | 32.31 | 78.12 | 19.71 | 25.54 | 90.73 | Upgrade | |
Revenue Growth (YoY) | -24.90% | -58.64% | 296.32% | -22.83% | -71.85% | 341.93% | Upgrade |
Cost of Revenue | 111.16 | 199.25 | 177.65 | 174.96 | 142.51 | 158 | Upgrade |
Gross Profit | -64.78 | -166.93 | -99.53 | -155.25 | -116.96 | -67.26 | Upgrade |
Selling, General & Admin | 54.9 | 71.99 | 69.65 | 70.7 | 76.18 | 67.58 | Upgrade |
Operating Expenses | 54.9 | 71.99 | 69.65 | 70.7 | 76.18 | 67.58 | Upgrade |
Operating Income | -119.68 | -238.92 | -169.18 | -225.95 | -193.15 | -134.84 | Upgrade |
Interest Expense | -6.64 | - | - | - | - | - | Upgrade |
Interest & Investment Income | 7.84 | 14.06 | 17.57 | 5.52 | 0.61 | 2.61 | Upgrade |
Other Non Operating Income (Expenses) | -2.18 | - | - | - | 0.04 | -0.11 | Upgrade |
EBT Excluding Unusual Items | -120.67 | -224.86 | -151.62 | -220.43 | -192.5 | -132.34 | Upgrade |
Merger & Restructuring Charges | -79.17 | -12.23 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -0 | -0 | -1.6 | - | - | 16.37 | Upgrade |
Pretax Income | -199.84 | -237.09 | -153.22 | -220.43 | -192.5 | -115.98 | Upgrade |
Net Income | -199.84 | -237.09 | -153.22 | -220.43 | -192.5 | -115.98 | Upgrade |
Net Income to Common | -199.84 | -237.09 | -153.22 | -220.43 | -192.5 | -115.98 | Upgrade |
Shares Outstanding (Basic) | 85 | 82 | 76 | 69 | 68 | 59 | Upgrade |
Shares Outstanding (Diluted) | 85 | 82 | 76 | 69 | 68 | 59 | Upgrade |
Shares Change (YoY) | 3.57% | 8.39% | 10.63% | 1.55% | 15.37% | 17.26% | Upgrade |
EPS (Basic) | -2.35 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | Upgrade |
EPS (Diluted) | -2.35 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | Upgrade |
Free Cash Flow | -180.7 | -219.11 | -136.9 | -181.47 | -171.78 | -187.01 | Upgrade |
Free Cash Flow Per Share | -2.12 | -2.66 | -1.80 | -2.64 | -2.54 | -3.19 | Upgrade |
Gross Margin | -139.66% | - | -127.40% | - | - | -74.13% | Upgrade |
Operating Margin | -258.03% | -739.37% | -216.56% | -1146.26% | -756.13% | -148.61% | Upgrade |
Profit Margin | -430.84% | -733.72% | -196.13% | -1118.26% | -753.61% | -127.82% | Upgrade |
Free Cash Flow Margin | -389.59% | -678.06% | -175.23% | -920.59% | -672.49% | -206.11% | Upgrade |
EBITDA | -112.04 | -233.11 | -163.12 | -219.61 | -188.09 | -130.88 | Upgrade |
EBITDA Margin | -241.55% | - | -208.80% | - | - | -144.25% | Upgrade |
D&A For EBITDA | 7.64 | 5.81 | 6.06 | 6.34 | 5.05 | 3.96 | Upgrade |
EBIT | -119.68 | -238.92 | -169.18 | -225.95 | -193.15 | -134.84 | Upgrade |
EBIT Margin | -258.03% | - | -216.56% | - | - | -148.61% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.